MedTrace Logo

Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors

NCT04855656 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 464

Last updated 2026-04-20

No results posted yet for this study

Summary

The primary purpose of this study is to assess the safety and tolerability of lunresertib alone and in combination with RP-3500 or in combination with Debio 0123 in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) and assess preliminary anti-tumor activity.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

Lunresertib

Oral PKMYT1 Inhibitor

DRUG

RP-3500

Oral ATR Inhibitor

DRUG

Debio0123

Oral WEE1 Inhibitor

Sponsors & Collaborators

  • Debiopharm International SA

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-30
Primary Completion
2027-12-31
Completion
2028-06-30
FDA Drug
Yes

Countries

  • United States
  • Canada
  • Denmark
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04855656 on ClinicalTrials.gov